There is limited experience with newer hypoglycemic agents such as sodium-glucose co-transporter inhibitor (SGLT2i, e.g., empagliflozin [39]), glucagon-like peptide-1 receptor agonist (GLP-1RA, e.g., liraglutide, dulaglutide [40,41] or peroxisome proliferator-activated receptor agonists (PPAR-A) which reduce systemic insulin resistance (e.g., pioglitazone [42]) in terms of neuroprotection post-stroke, as their investigations have focused on demonstrating the prevention of stroke or other long-term sequalae rather than improving the outcome from it [39,40,41,42]. Here, INS is linked to Stroke.